898 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft purchased a new stake in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 898 shares of the medical instruments supplier’s stock, valued at approximately $234,000.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial acquired a new position in shares of Insulet during the fourth quarter worth $57,000. Finally, Versant Capital Management Inc increased its holdings in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares during the last quarter.

Insulet Stock Down 0.6 %

Insulet stock opened at $278.38 on Friday. The stock has a market capitalization of $19.53 billion, a price-to-earnings ratio of 47.67, a PEG ratio of 3.48 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a 50 day moving average of $268.69 and a two-hundred day moving average of $237.96. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $286.39.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. During the same period last year, the firm posted $0.71 EPS. As a group, research analysts expect that Insulet Co. will post 3.22 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PODD has been the subject of a number of recent analyst reports. Citigroup lifted their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.